Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGULUS THERAPEUTICS INC.

(RGLS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2021 10/21/2021 10/22/2021 10/25/2021 10/26/2021 Date
0.4742(c) 0.472(c) 0.441(c) 0.445(c) 0.5018(c) Last
2 977 257 2 674 312 4 864 038 2 812 704 7 367 650 Volume
-2.23% -0.46% -6.57% +0.91% +12.76% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,01 M - -
Net income 2021 -24,8 M - -
Net cash position 2021 25,3 M - -
P/E ratio 2021 -1,61x
Yield 2021 -
Sales 2022 0,02 M - -
Net income 2022 -27,6 M - -
Net Debt 2022 0,21 M - -
P/E ratio 2022 -1,61x
Yield 2022 -
Capitalization 43,7 M 43,7 M -
EV / Sales 2021 2 046x
EV / Sales 2022 2 438x
Nbr of Employees 25
Free-Float 94,0%
More Financials
Company
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR... 
More about the company
Ratings of Regulus Therapeutics Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about REGULUS THERAPEUTICS INC.
10/18REGULUS THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/13AFTER HOURS WATCH LIST SCORECARD : Vst, stim, rgls
MT
10/13Health Care Stocks Edging Higher Ahead of Wednesday Close
MT
10/13Health Care Stocks Finding Increased Support This Afternoon
MT
10/13Wall Street Wavers Pre-Bell as US Consumer Prices Rise More Than Expected, Fed Minutes ..
MT
10/13Top Premarket Decliners
MT
10/12MT NEWSWIRES AFTER HOURS WATCH LIST : Vst, stim, rgls
MT
10/12REGULUS THERAPEUTICS : Shifting Development Focus to Next-Generation Kidney Drug; Stock Pl..
MT
10/12REGULUS THERAPEUTICS INC. : Other Events (form 8-K)
AQ
10/12REGULUS THERAPEUTICS : Announces Strategic Prioritization of RGLS8429, its Next-Generation..
PR
10/12Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generatio..
CI
09/09REGULUS THERAPEUTICS : to Present at the H.C. Wainwright 23rd Annual Global Investment Con..
PR
09/02REGULUS THERAPEUTICS : Cantor Fitzgerald Reinstates Regulus Therapeutics at Overweight wit..
MT
08/10REGULUS THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
08/10REGULUS : Q2 Earnings Snapshot
AQ
More news
News in other languages on REGULUS THERAPEUTICS INC.
10/13Les actions du secteur de la santé en hausse avant la clôture de mercredi
10/13Les actions du secteur de la santé trouvent un soutien accru cet après-midi
10/12Regulus Therapeutics se concentre sur le développement d'une nouvelle génération de méd..
04/07DGAP-HV : Fresenius Medical Care AG & Co. KGaA: -4-
More news
Analyst Recommendations on REGULUS THERAPEUTICS INC.
More recommendations
Chart REGULUS THERAPEUTICS INC.
Duration : Period :
Regulus Therapeutics Inc. Technical Analysis Chart | RGLS | US75915K2006 | MarketScreener
Technical analysis trends REGULUS THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 0,50 $
Average target price 1,38 $
Spread / Average Target 174%
EPS Revisions
Managers and Directors
Joseph P. Hagan President, Chief Executive Officer & Director
Crispina Calsada Chief Financial Officer
Stelios Papadopoulos Chairman
Denis Drygin Chief Scientific Officer
David Baltimore Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REGULUS THERAPEUTICS INC.-62.83%44
MODERNA, INC.230.95%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.42.93%48 923
SEAGEN INC.1.46%32 330
CELLTRION, INC.-38.02%26 036